Cerus Corporation (CERS)

Market Cap	449.48M
Revenue (ttm)	199.19M +13.0%
Net Income	-15.96M
EPS	-0.08
Shares Out	192.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	546,810
Open	2.340
Previous Close	2.360
Day's Range	2.290 - 2.380
52-Week Range	1.120 - 2.955
Beta	1.52
Analysts	Buy
Price Target	4.00 (+70.94%)
Earnings Date	Feb 19, 2026

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 1997
• Employees: 630
• Stock Exchange: NASDAQ
• Ticker Symbol: CERS
• Website: https://www.cerus.com

Financial Performance

In 2024, Cerus's revenue was $180.27 million, an increase of 15.29% compared to the previous year's $156.37 million. Losses were -$20.92 million, -44.20% less than in 2023.

Analyst Summary

According to one analyst, the rating for CERS stock is "Buy" and the 12-month stock price target is $4.0.

Price Target

$4.0

(70.94% upside)

Analyst Consensus: Buy